论文部分内容阅读
目的:调查我院初诊2型糖尿病的老年患者常用的三组口服降糖药物治疗方案,进行3个治疗方案的成本-效果分析,并了解低血糖发生比例,为老年患者选择降糖治疗方案提供参考。方法:采用回顾性调查,将我院初诊2型糖尿病的老年患者,均在口服二甲双胍的基础上,A组加用格列美脲,B组加用瑞格列奈,C组加用吡格列酮,采集监测的血糖值和糖化血红蛋白作为效果测量指标,进行成本-效果分析,并统计低血糖发生次数。结果:三组间患者的基本情况比较,差异无统计学意义(P>0.05)。ABC组治疗方案的药物成本均数为675.15元,875.95元,650.15元,3组治疗方案效价比A组大于B、C组,B组和C组之间无统计学差异,A组发生低血糖比例明显大于B、C组。结论:对于2型糖尿病患者的初始治疗,选用格列美脲联合二甲双胍的治疗方案效价比高,但低血糖发生率高。高龄、智能和认知障碍、自理能力差、肝肾功能减退、预计远期寿命较短的患者可选择使用瑞格列奈的治疗方案。
OBJECTIVE: To investigate the cost-benefit analysis of three treatment regimens commonly used in elderly patients with newly diagnosed type 2 diabetes in our hospital and to understand the incidence of hypoglycaemia and provide the treatment options for elderly patients undergoing hypoglycemic treatment reference. Methods: Based on the retrospective investigation, elderly patients with newly diagnosed type 2 diabetes mellitus were treated with glimepiride in group A, repaglinide in group B, and pioglitazone in group C, Collect the monitored blood glucose and glycosylated hemoglobin as a measure of effectiveness, perform a cost-benefit analysis, and count the number of hypoglycemic episodes. Results: There was no significant difference in the basic conditions between the three groups (P> 0.05). The mean cost of medication in ABC group was 675.15 yuan, 875.95 yuan and 650.15 yuan respectively. There was no significant difference between the three groups in the treatment program titer than in group A, B, C, B and C Blood glucose was significantly greater than the B, C group. CONCLUSIONS: For initial treatment of type 2 diabetic patients, treatment with glimepiride combined with metformin is cost-effective but with a high incidence of hypoglycaemia. Older age, intellectual and cognitive disorders, poor self-care ability, diminished liver and kidney function, and the expected short-term life expectancy of patients may choose to use repaglinide treatment options.